Supplemental Figure S3 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

openalex（2023）

引用 0|浏览13

暂无评分

摘要

MET tyrosine kinase domain modeling location of the F1200 residue

查看译文

关键词

ras–mapk pathway limit response,met inhibitor treatment,cancer,met exon,co-occurring,mutation-positive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要